These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27673482)

  • 1. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
    Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
    J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
    Xiong Y; Zhang M; Li Y
    Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
    Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
    Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
    Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
    J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
    Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
    Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
    Zucconi BE; Makofske JL; Meyers DJ; Hwang Y; Wu M; Kuroda MI; Cole PA
    Biochemistry; 2019 Apr; 58(16):2133-2143. PubMed ID: 30924641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
    Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
    Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation.
    Delvecchio M; Gaucher J; Aguilar-Gurrieri C; Ortega E; Panne D
    Nat Struct Mol Biol; 2013 Sep; 20(9):1040-6. PubMed ID: 23934153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
    Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
    Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation.
    Olzscha H; Fedorov O; Kessler BM; Knapp S; La Thangue NB
    Cell Chem Biol; 2017 Jan; 24(1):9-23. PubMed ID: 27989401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
    Strachowska M; Robaszkiewicz A
    Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
    Suryanarayanan V; Singh SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.
    Huang L; Li H; Li L; Niu L; Seupel R; Wu C; Cheng W; Chen C; Ding B; Brennan PE; Yang S
    J Med Chem; 2019 May; 62(9):4526-4542. PubMed ID: 30998845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
    Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
    Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.
    Humphreys PG; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Hayhow TG; Hussain J; Jones KL; Lindon M; Michon AM; Renaux JF; Suckling CJ; Tough DF; Prinjha RK
    J Med Chem; 2017 Jan; 60(2):695-709. PubMed ID: 28002667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
    Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
    Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.